Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus

The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gem...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutch, Manish, Joshi, Abhay, Kumar, Sukriti, Agarwal, Avinash, Pahan, Rajendra Kumar, Razi, Syed Mohd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729681/
https://www.ncbi.nlm.nih.gov/pubmed/29285456
http://dx.doi.org/10.4103/ijem.IJEM_20_17
Descripción
Sumario:The dipeptidyl peptidase-4 (DPP-4) inhibitors have facilitated the management of type 2 diabetes mellitus (T2DM) owing to their superior efficacy and safety with low incidence of adverse effects. Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners. Besides, this drug has also been studied for the treatment of T2DM as monotherapy, in combination with metformin or other oral antidiabetic drugs and in T2DM with moderate-to-severe renal failure. In this review, we explore the published data highlighting the pharmacology, efficacy, and safety of gemigliptin along with its recommendations for use in patients with T2DM.

Ejemplares similares